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Background and PurposezzDuchenne and Becker muscular dystrophies are the most com-
mon X-linked recessive muscular dystrophies. Dystrophin gene mutations usually affect men, 
but reportedly 2.5–7.8% of women are affected and are classified as symptomatic carriers. The 
aim of this study was to clinically and genetically characterize symptomatic female dystrophi-
nopathy carriers.
MethodszzThe clinical and genetic data of 11 female dystrophinopathy carriers among 285 pa-
tients who underwent multiplex ligation-dependent probe amplification (MLPA) analysis for 
the dystrophin gene were reviewed. Women with muscle weakness and/or dilated cardiomy-
opathy were classified as symptomatic carriers, while subjects with high serum creatine kinase 
(CK) levels and/or minor myopathic signs such as muscle cramps and myalgia were classified 
as asymptomatic.
ResultszzTwelve female carriers were identified, but 1 symptomatic carrier who also had Turn-
er syndrome was excluded from the study. Of the 11 included female carriers, 4 were symptom-
atic and 7 were asymptomatic. The age at symptom onset in the symptomatic female carriers 
ranged from 15 to 31 years (mean, 30.6 years), and the age at diagnosis for asymptomatic car-
riers ranged from 4 to 38 years (mean, 24.5 years). Serum CK levels were markedly elevated 
(mean, 1,301 IU/mL) in three of the four (75%) symptomatic female carriers, and mildly ele-
vated in three of the seven (42%) asymptomatic female carriers. Symptomatic female carriers 
typically presented with asymmetric bilateral leg weakness as the initial symptom, with aggra-
vated symptoms after labor.
ConclusionszzFemale dystrophinopathy is not uncommon, and it is an important factor with 
respect to males with dystrophinopathy who may be born to such patients. Screening with MLPA 
is useful because it can aid in early diagnosis and appropriate management.
Key Wordszz dystrophinopathy, female, multiplex ligation-dependent probe amplification.
Clinical and Genetic Characterization  
of Female Dystrophinopathy
INTRODUCTION
Duchenne and Becker muscular dystrophies (DMD and BMD, respectively) are the most 
common X-linked recessive muscular dystrophies caused by mutations in the dystrophin 
gene that encodes a muscle cytoskeletal protein.1 Muscular dystrophy is also called dystro-
phinopathy because it is caused by mutations in the DMD gene—which encodes dystro-
phin—at the Xp21 locus.2 DMD is the more severe form of dystrophinopathy and is caused 
by a frameshift mutation.1 Patients with BMD usually carry in-frame mutations that lead 
to amino acid translations, and therefore manifest a milder phenotype that is characterized 
by muscle weakness, exercise intolerance, myoglobinuria, and myalgia.1 DMD and BMD 
usually affect men, but women also occasionally develop symptoms, and two-thirds of moth-
ers of affected males are thought to be DMD carriers.3
Reportedly 2.5–7.8% of female DMD carriers report muscle weakness and are therefore 
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classified as manifesting DMD carriers.2-4 Hoogerwaard et al. 
found that 5% of female DMD carriers present with regular 
myalgia and cramps without muscle weakness, 17% experience 
mild-to-moderate muscle weakness, and 8% present with 
dilated cardiomyopathy, with an average onset age of 33 
years.5 Since most heterozygous female carriers of DMD have 
subclinical symptoms, screening of dystrophinopathy carri-
ers may only be performed on clinical grounds such as a clear 
X-linked family history of muscular dystrophy.6 However, 
myopathic muscle biopsy and advanced molecular diagnos-
tic analysis can be used to identify DMD carriers who do not 
have a positive family history of dystrophinopathy; 10% of 
women with abnormally elevated serum creatine kinase (CK) 
are DMD carriers.3 The clinical characteristics of genetically 
confirmed female dystrophinopathy carriers were explored 
in this study.
METHODS
The database records from Gangnam Severance Hospital in 
South Korea collected between July 2007 and October 2013 
were searched for women with clinical features indicative of 
dystrophin gene mutations. As in previous studies,5,7-9 female 
carriers were classified as symptomatic when they manifest-
ed symptoms of muscle weakness and/or dilated cardiomy-
opathy, and as asymptomatic when they exhibited high se-
rum levels of CK and/or minor myopathic signs such as muscle 
cramps and myalgia, but did not have muscle weakness or di-
lated cardiomyopathy.5 Isolated CK elevation alone would 
not be sufficient to consider a patient as a manifesting carri-
er.9 A diagnosis of dystrophinopathy is usually considered af-
ter careful review of the subject’s clinical features, family his-
tory, and laboratory evidence of elevated serum CK. Cases 
were confirmed through examinations such as muscle biop-
sy or molecular genetic testing. DMD mutation analysis em-
ploying a combination of techniques was applied to DNA ex-
tracted from peripheral blood.8 Intragenic deletions and 
duplications were analyzed using [multiplex ligation-depen-
dent probe amplification (MLPA); MRC-Holland, Amster-
dam, The Netherlands].10 The following data were collected 
retrospectively for symptomatic female carriers: clinical fea-
tures, ages at onset and diagnosis, serum CK levels, and find-
ings of cardiology tests, electromyography, muscle MRI, and 
muscle biopsy analysis.
RESULTS
Of the 285 patients (230 men and 55 women) who were screened 
for dystrophin gene mutations, 104 men and 12 women with 
mutations were identified; 1 symptomatic female carrier who 
also had Turner syndrome was excluded. Among the includ-
ed 11 female carriers, 4 were symptomatic and 7 were as-
ymptomatic (Fig. 1). The most common reason for asymp-
tomatic female carriers visiting the hospital was a family 
history of muscular dystrophy. The clinical presentations and 
detected gene mutations in symptomatic female carriers are 
summarized in Table 1.
Two of the symptomatic women had out-of-frame dele-
tions and two had duplications. The mutation sites in both 
patients with deletions were distributed in hot-spot lesions 
(exons 2–20 and 44–53). Of the seven asymptomatic female 
carriers, six had out-of-frame deletions and only one had a 
duplication (Fig. 1). In the symptomatic dystrophinopathy 
carriers, the age at symptom onset varied from 15 to 31 years 
(mean, 30.6 years), and the age at diagnosis varied from 30 to 
35 years (mean, 34.5 years). The ages at diagnosis in the sev-
en asymptomatic carriers were 4, 22, 26, 27, 27, 28, and 38 
years (mean, 24.5 years). Serum CK levels were elevated (mean, 
1,301 IU/mL normal range, 35–232 IU/mL) in three of the 
four (75%) symptomatic female carriers, but only mild in-
creases (mean, 347 IU/mL) were noted in three of the seven 
(42%) asymptomatic female carriers.
DISCUSSION
Several mechanisms have been proposed to explain symp-
tom manifestation in women with DMD/BMD.5-9 The most 
frequently reported mechanisms are skewed X-chromosome 
inactivation (XCI), in which expression of the X chromosome 
with the DMD mutated allele is favored,11 and balanced X-
autosome translocation.12 The relationship between XCI and 
clinical severity is not clear, and the prognostic value of XCI 
is controversial.11 As observed in the present study, some wom-
en with Turner syndrome have a dystrophin mutation on the 
remaining X chromosome,13 and others have a dystrophin 
mutation on each X chromosome. There are also rare cases 
of dystrophin mutations in females with X chromosome uni-
Female carriers 
(n=11)
Symptomatic 
carriers (n=4)
Deletion of exons
(n=2, 50%)
Deletion of exons
(n=6, 85.7%)
Duplication of
exons (n=2, 50%)
Duplication of
exons (n=1, 14.3%)
Asymptomatic
carriers (n=7)
Fig. 1. Results of multiplex ligation-dependent probe amplification 
analysis of the dystrophin gene in women with dystrophinopathy.
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parental disonomy,14 and in male pseudohermaphrodites with 
mutations in the androgen receptor gene.15
The diagnostic approach to female dystrophinopathy in-
cludes a clinical history of myopathic symptoms and signs as 
well as a family history. The presence of elevated serum CK 
is an important indicator of carrier status, but this occurs in 
only about 70% of carriers, so a normal CK level does not ex-
clude the possibility of being a carrier. Electromyography, MRI 
analysis, muscle biopsy with dystrophin immunostaining, 
and DNA analysis are the predominant tests used for deter-
mining the presence of dystrophinopathy. The exclusion of 
other types of neuromuscular diseases is also important for 
diagnosing dystrophinopathy.
Dystrophin gene mutation analysis reveals a deletion of one 
or more exons in 60–70% of dystrophinopathy cases.10,16 DMD 
gene duplications account for 5–15% of DMD cases, and point 
mutations or small deletions/insertions account for 25–
30%.16,17 The multiplex polymerase chain reaction is a com-
mon technique used to identify DMD gene mutations, and 
it can detect approximately 98% of deletions; however, it is 
not useful for detecting duplications or identifying female 
carriers.10 Conversely, MLPA can detect the deletions and du-
plications in both male and female carriers, and so this pro-
cedure is currently the gold standard for DMD gene molec-
ular analysis.10 Unlike male DMD patients, manifesting female 
carriers have variable disease activity and can even be asymp-
tomatic, and so their status can go undetected.18
The symptomatic female carriers in this study were char-
acterized clinically and genetically. First, the age at symptom 
onset in these patients was addressed. In previous studies the 
mean symptom onset age for female carriers was 33.6 years,5 
compared to 39.6 years for cardiomyopathy.19 In contrast, 
male patients with DMD exhibit their first symptoms at 3.0± 
1.8 years (mean±SD), while patients with DMD varied in their 
symptom presentation (mainly elevated serum CK, weakness, 
fatigue, myalgia, or cramps) at the age of 12.9±11.8 years.20,21 
In the present study, the age at symptom onset among the fe-
male carriers ranged from 15 to 31 years (mean, 30.6 years), 
and the age at diagnosis for asymptomatic carriers ranged 
from 4 to 38 years (mean, 24.5 years). Muscular dystrophy is 
a progressive disease, and the age at symptom onset in female 
carriers is far older than would be expected for homozygous 
male patients carrying the same mutation. The present find-
ings suggest that asymptomatic female carriers should be fol-
lowed up because they were younger at diagnosis than the age 
at symptom onset in symptomatic carriers, and most were 
evaluated before pregnancy.
Elevated serum CK levels were found in the present symp-
tomatic female carriers, while only asymptomatic female car-
riers exhibited mildly elevated CK levels. Serum CK measure-
Ta
bl
e 
1.
 C
lin
ic
al
 fe
at
ur
es
 a
nd
 d
et
ec
te
d 
m
ut
at
io
ns
 in
 s
ym
pt
om
at
ic
 fe
m
al
e 
dy
st
ro
ph
in
op
at
hy
 c
ar
rie
rs
ID
Ag
e 
at
 d
ia
gn
os
is
(y
ea
rs
)
Ag
e 
at
 o
ns
et
(y
ea
rs
)
Ge
ne
Fr
am
e
In
iti
al
 
sy
m
pt
om
O
th
er
ch
ar
ac
te
ris
tic
Dy
sp
ne
a
Cl
in
ic
al
 fi
nd
in
gs
CK
 
(IU
/m
L)
EK
G
Ec
ho
EM
G
Bi
op
sy
FH
x
1
30
22
Du
pl
ic
at
io
n 
of
  e
xo
ns
 3
–3
7
-
W
ea
kn
es
s
  o
f b
ot
h 
le
gs
*
Ag
gr
av
at
io
n
  a
ft
er
 la
bo
r
Ye
s
G
ow
er
’s 
sig
n 
(+
) 
Ps
eu
do
hy
pe
rt
ro
ph
y
1,
35
8
W
N
L
W
N
L
M
yo
ge
ni
c
M
yo
ge
ni
c
Ye
s
2
38
31
Du
pl
ic
at
io
n 
of
  e
xo
ns
 5
2,
 5
3,
  a
nd
 5
6–
61
-
W
ea
kn
es
s
  o
f b
ot
h 
le
gs
*
Ag
gr
av
at
io
n
  a
ft
er
 la
bo
r
Ye
s
G
ow
er
’s 
sig
n 
(+
) 
Ps
eu
do
hy
pe
rt
ro
ph
y
1,
35
0
RV
H
W
N
L
N
D
M
yo
ge
ni
c
Ye
s
3
34
15
De
le
tio
n 
of
  e
xo
ns
 4
8–
52
Ou
t o
f f
ra
m
e
W
ea
kn
es
s
  o
f b
ot
h 
le
gs
*
Ag
gr
av
at
io
n
  a
ft
er
 la
bo
r
N
o
G
ow
er
’s 
sig
n 
(+
) 
Ps
eu
do
hy
pe
rt
ro
ph
y
N
D
N
D
N
D
N
D
N
D
Ye
s
4
35
25
De
le
tio
n 
of
  e
xo
ns
 4
6–
48
Ou
t o
f f
ra
m
e
W
ea
kn
es
s
  o
f b
ot
h 
le
gs
*
Ag
gr
av
at
io
n
  a
ft
er
 la
bo
r
N
o
G
ow
er
’s 
sig
n 
(+
) 
Ps
eu
do
hy
pe
rt
ro
ph
y
1,
19
5
W
N
L
W
N
L
W
N
L
N
D
N
o
*A
sy
m
m
et
ry
.
CK
: c
re
at
in
e 
ki
na
se
, F
H
x:
 fa
m
ily
 h
ist
or
y, 
ID
: p
at
ie
nt
 id
en
tifi
ca
tio
n 
nu
m
be
r, 
N
D:
 n
ot
 d
on
e,
 R
VH
: r
ig
ht
-v
en
tr
ic
ul
ar
 h
yp
er
tr
op
hy
, W
N
L:
 w
ith
in
 n
or
m
al
 li
m
its
, (
+)
: p
os
iti
ve
.
www.thejcn.com  251
Lee SH et al. JCN
ment is the most commonly used method for carrier detection,22 
and elevated levels are found in up to 50% of carriers.5 Inter-
estingly, all symptomatic female carriers in the present study 
manifested bilateral leg weakness as the initial symptom. Con-
sistent with previous reports,7,23 three of the four patients (75%) 
reported asymmetric muscle weakness, which has previous-
ly been reported as being present in between 15% and 81% 
of symptomatic carriers.3,5,23 Muscle MRI in female carriers is 
more sensitive than clinical examination for detecting single-
muscle involvement and asymmetry.7 Finally, symptom se-
verity—exacerbated muscle weakness—in the symptomatic 
female carriers was aggravated after giving birth (Table 1). Giv-
en that dystrophinopathy is typically studied in males, the 
association between female dystrophinopathy and labor has 
not previously been explored, and asymptomatic female car-
riers should be closely monitored for symptoms during and 
after labor.
The findings of this study should be interpreted with cau-
tion in the light of certain limitations. For example, relatively 
few patients were included and the retrospective design of the 
study meant that chromosome or XCI studies could not be 
performed. Further studies with larger samples are needed to 
determine whether the present findings are generalizable to 
broad patient populations.
Female symptomatic dystrophinopathy is a rare condition 
whose diagnosis can be challenging. The MLPA method is a 
simple, rapid, and reliable tool for screening for DMD/BMD 
gene mutations. Since female dystrophinopathies are impor-
tant factors that affect the prevalence of DMD/BMD in males, 
early diagnosis of DMD/BMD and appropriate genetic coun-
seling are needed. In conclusion, understanding and charac-
terizing female dystrophinopathy is helpful for the establish-
ment of diagnostic approaches in patients with a negative family 
history who may have been wrongly diagnosed with limb-gir-
dle muscular dystrophy, inflammatory myositis, or an unknown 
myopathy.
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